Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. It ensures timely delivery and reliable supply chain management for its partners.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): reduces HbA1c levels and improves fasting glucose as an add‑on to diet and exercise. - Type 2 diabetes mellitus (combination therapy): enhances glycaemic control when combined with metformin, sulfonylureas or insulin. - Type 2 diabetes with renal impairment: provides glucose control without the need for dose adjustment in patients with reduced kidney function.

Linagliptin may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Upper respiratory tract infection - Nasopharyngitis - Headache - Dizziness - Gastrointestinal discomfort (nausea, abdominal pain) - Skin rash

Serious or Rare Side Effects: - Pancreatitis - Severe hypersensitivity reactions (angioedema, anaphylaxis) - Hepatic enzyme elevations - Bullous pemphigoid - Hypoglycaemia when combined with insulin or sulfonylureas

When prescribing linagliptin, clinicians should consider several safety aspects.

- Renal impairment: no dose adjustment required but monitor renal function regularly. - Hepatic impairment: use with caution in patients with moderate hepatic disease. - Concomitant sulfonylureas or insulin: increased risk of hypoglycaemia; adjust co‑medication as needed. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks. - Cardiovascular disease: no specific contraindication, but monitor patients with unstable cardiac conditions. - Store at ambient temperature (below 25 °C): keep in the original packaging, protect from moisture and light.

Linagliptin can interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin) may markedly reduce linagliptin exposure. - Co‑administration with insulin secretagogues may precipitate severe hypoglycaemia. - Use with other DPP‑4 inhibitors is not recommended due to overlapping mechanisms.

Moderate Interactions (Monitor Closely): - Diuretics may increase the risk of dehydration. - ACE inhibitors may enhance hypotensive effects. - Anticoagulants (e.g., warfarin) may require INR monitoring. - Antacids containing aluminium/magnesium may slightly affect absorption. - NSAIDs may increase the risk of renal impairment in susceptible patients.